Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin
Overview
The identification of all cases (44 patients) was carried out from the database of microbiology, University Hospital Reina Sofía and the University Hospital of Jerez. For the identification of controls, in case of neutropenic patients, all colonized patients that were included during the study period did not receive any decolonitation treatment; in case of non-neutropenic patients it was studied a paired control by the presence of risk factors that indicated the beginning of decolonitation treatment.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: July 2015
Interventions
- Drug: Neomycin
- Drug: Streptomycin
- Drug: Gentamicins
Arms, Groups and Cohorts
- Received therapy desconolizacion against Klebsiella pneumoniae
- Patients who do not receive the therapy
Clinical Trial Outcome Measures
Primary Measures
- Mortality for any cause during a six-months period after oral therapy gut decontamination.
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- Patients with intestinal colonization by Klebsiella pneumoniae, defined as the presence of a positive rectal swab culture at least 7 days prior to initiation of therapy; and patients considered at risk of developing an invasive infection by Klebsiella pneumoniae: – Surgery in two weeks – Transplant in two weeks – Require medical intervention or has a clinical situation that may predispose to the development of a serious infection (chemotherapy, immunosuppression or neutropenia) – Recurrent or severe infections – Institution admission – Fragile patients at high risk of readmission. Exclusion Criteria:
- The presence of an active infection for Klebsiella Pneumoniae. – Concomitant use of systemic antibiotics in the 14 days before the start of decolonization therapy.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Maimónides Biomedical Research Institute of Córdoba
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.